Showing 621-630 of 725 results for "".
- Commercialization of MelaFind Now Underwayhttps://practicaldermatology.com/news/20120314-commercialization_of_melafind_now_underway/2459843/MELA Sciences, Inc. (NASDAQ: MELA) this week announced that the company has begun commercialization of MelaFind, as part of a controlled and deliberate launch in the U.S. and in Germany. "We are enthusiastic about the success of our final b
- Cellceutix Files pre-IND Submission for Prurisol for Psoriasishttps://practicaldermatology.com/news/20120312-cellceutix_files_pre-ind_submission_for_prurisol_for_psoriasis/2459849/Cellceutix Corporation (OTCBB: CTIX) filed a pre-IND submission with the FDA for Prurisol (also termed KM-133), a drug in development for treatment of psoriasis. The company is seeking guidance to attain approval for a section 505(b)(2) designa
- Dr. April Armstrong Previews New Era for Oral Psoriasis Treatmentshttps://practicaldermatology.com/news/dr-april-armstrong-previews-new-era-for-oral-psoriasis-treatments/2485362/From wild chickens roaming Maui to a growing flock of groundbreaking psoriasis therapies, April W. Armstrong, MD, MPH, delivered an optimistic update on the future of plaque psoriasis treatment during a presentation at the 2026 Winter Clinical Dermatology Conference in Hawaii. “Psoriasis d
- Dr. Darrell Rigel Highlights Urgent Skin Cancer Trends at Winter Clinical 2026https://practicaldermatology.com/news/dr-darrell-rigel-highlights-urgent-skin-cancer-trends-at-winter-clinical-2026/2485361/Skin cancer continues its upward trajectory, with new data showing that one in 19 Americans will be diagnosed with melanoma in their lifetime. This alarming statistic headlined a wide-ranging presentation by Darrell S. Rigel, MD, MS, at the 2026 Winter Clinical Dermatology Conference in Hawaii, w
- Survey Reveals Clinician Views on CHE's Impact on Quality of Lifehttps://practicaldermatology.com/news/Survey-Reveals-Clinician-Views-CHEs-Impact-Quality-Life/2474228/Ninety-five percent of US dermatology clinicians surveyed agreed moderate-to-severe chronic hand eczema (CHE) has a strong impact on patients’ work and home life, according to the second phase of a survey sponsored by LEO Pharma Inc., the company announced in a press release. The survey, w
- Registration Opens for the Tell-All Tribune and Genesis Meetingshttps://practicaldermatology.com/news/Registration-Opens-Tell-All-Tribune-Genesis-Meetings/2471850/Registration is open for two Modern Aesthetics meetings that were overwhelmingly popular in 2024 and now will be held on the same weekend, June 20-21, at the W Hotel in Fort Lauderdale, Florida. The Tell-All Tribune: An Aesthetic Think Tank, which was an invitation-only event in its inaugu
- DELTA TEEN: Positive Results for Delgocitinib in Adolescent Chronic Hand Eczemahttps://practicaldermatology.com/news/delta-teen-positive-results-for-delgocitinib-in-adolescent-chronic-hand-eczema/2471096/Phase 3 data from the DELTA TEEN trial demonstrated that Anzupgo® (delgocitinib) cream achieved significant improvements in symptoms of moderate to severe chronic hand eczema (CHE) in adolescents aged 12–17, according to a news release from the manufacturer. The DELTA TEEN trial was a 16-w
- Study: PLLA-SCA Induces Adipogenesis and Volumization of the Hip Dellhttps://practicaldermatology.com/news/study-plla-sca-induces-adipogenesis-and-volumization-hip-dell/2468575/Injecting poly-l-lactic acid (PLLA-SCA) is a safe and effective method for durable volumization and aesthetic improvement of the hip dell, and may promote adipogenesis and elastogenesis, according to a new study published in Dermatologic Surgery. “People have used Sculptra for years, but w
- Dupilumab Reduces Inflammatory Biomarkers in Pediatric AD: Studyhttps://practicaldermatology.com/news/dupilumab-reduces-inflammatory-biomarkers-pediatric-ad/2467953/Dupilumab significantly reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis (AD), according to results from recent phase 3 trials. Pediatric patients treated with dupilumab demonstrated substantial reductions in key serum biomarkers associated w
- Merck Discontinues Testing of Experimental Skin Cancer Combo Therapyhttps://practicaldermatology.com/news/merck-discontinues-testing-experimental-skin-cancer-combo-therapy/2463022/Merck has announced the termination of the vibostolimab and pembrolizumab coformulation arm in the Phase 3 KeyVibe-010 trial, according to a news release from the company. The trial assessed the combination therapy's efficacy compared to KEYTRUDA alone as adjuvant treatment for patients w